Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.biopha.2021.111785 http://scihub22266oqcxt.onion/10.1016/j.biopha.2021.111785 34126316!8162906!34126316     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Pharmacother 2021 ; 140 (ä): 111785 Nephropedia Template TP {{tp|p=34126316|t=2021. Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 |pdf=|usr=}}{{34126316}} gab.com Text Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 JO: Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34126316 #FOAvip Coronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor are significant in the pathogenesis of COVID-19 and associated with poor outcomes including ventilator requirement and mortality. Repurposing tumour necrosis factor blocker therapy used in conditions such as rheumatoid arthritis and inflammatory bowel disease seems promising, with early feasibility data showing a reduction in circulation of pro-inflammatory cytokines and encouraging the evaluation of such interventions in preventing disease progression and clinical deterioration in patients with COVID-19. Here, we examine the biological activities of tumour necrosis factor inhibitors indicative of their potential in COVID-19 and briefly outline the randomised control trials assessing their benefit-risk profile in COVID-19 therapy. Twit Text FOAVip Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 ????Biomed Pharmacother http://www.kidney.de/pget.php?&tw=1&pmid=34126316 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34126316 #FOAvip English Wikipedia <ref>{{Cite pmid|34126316}}</ref> Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19 #MMPMID34126316 Patel S; Wadhwa M Biomed Pharmacother 2021[Aug]; 140 (ä): 111785 PMID34126316show ga Coronavirus disease 2019 (COVID-19) has caused significant devastation globally. Despite the development of several vaccines, with uncertainty around global uptake and vaccine efficacy, the need for effective therapeutic agents remains. Increased levels of cytokines including tumour necrosis factor are significant in the pathogenesis of COVID-19 and associated with poor outcomes including ventilator requirement and mortality. Repurposing tumour necrosis factor blocker therapy used in conditions such as rheumatoid arthritis and inflammatory bowel disease seems promising, with early feasibility data showing a reduction in circulation of pro-inflammatory cytokines and encouraging the evaluation of such interventions in preventing disease progression and clinical deterioration in patients with COVID-19. Here, we examine the biological activities of tumour necrosis factor inhibitors indicative of their potential in COVID-19 and briefly outline the randomised control trials assessing their benefit-risk profile in COVID-19 therapy. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |COVID-19/metabolism[MESH] |Cytokines/metabolism[MESH] |Humans[MESH] |Inflammation/*drug therapy/metabolism[MESH] |SARS-CoV-2/*drug effects[MESH]Therapeutic use of specific tumour necrosis factor inhibitors in infla(epmc).pdf DeepDyve Pubget Overpricing